Waters, NIBRT Partner to Grow Knowledge of Large-Molecule Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters, NIBRT Partner to Grow Knowledge of Large-Molecule Characterization


ePT--the Electronic Newsletter of Pharmaceutical Technology

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The two organizations established the Complete Product and Processing Characterization Facility for hands-on laboratory-based scientific training and retraining of “fit-for-purpose” biopharmaceutical analysis, including protein and peptide characterization. The goal of the facility is to provide comprehensive training of industry and governmental technicians and scientists in an effort to develop advanced biotherapeutic characterization Training on US and European drug regulations will also be offered. Finally, the partnership establishes NIBRT as a Waters Center of Innovation in the area of glycobiology research.

“Ireland is a leading location globally for the development and manufacture of complex biopharmaceutical drugs. This is due in large part to a sustained commitment to quality and compliance with the highest regulatory standards,” said NIBRT’s Interim Director Prof. Ian Marison.

“Through this lab and other collaborations, Waters will work with industry to improve the development of biopharmaceuticals and inform governments on the types of regulations that should be put in place,” said Mike Harrington, Waters vice-president, European Operations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here